Form 4: Corcept Therapeutics Executive Sean Maduck Reports Stock Transactions

Sean Maduck, President of Corcept Endocrinology, reports stock transactions including option exercises, stock sales, and tax withholding related to restricted stock units.

Summary

• Sean Maduck, President of Corcept Endocrinology, filed a Form 4 detailing changes in beneficial ownership of Corcept Therapeutics (CORT) stock.
• The transactions occurred on March 3, 2025, and include the exercise of stock options, sales of common stock, and tax withholding related to restricted stock units.
• Maduck exercised 18,303 stock options at a price of $5.05.
• He also sold 18,303 shares at a weighted average price of $60.6905.
• 228 shares were withheld by the issuer to cover tax obligations related to vesting restricted stock units at a price of $60.58.
• Maduck purchased 266 shares at $59.07 and received 266 shares under a purchase plan at $0.
• Following these transactions, Maduck directly owns 85,622 shares of common stock.
• He also indirectly owns 10,000 shares through Duckhill Capital, LLC and 10,000 shares through the Sean and Molly Maduck Living Trust.
• Maduck was also granted 140,000 stock options exercisable at $60.58, vesting monthly from February 28, 2025, to February 28, 2035.

Sentiment

Score: 6

Explanation: Neutral sentiment. The transactions are typical for executive compensation and do not indicate any significant positive or negative developments for the company.

Positives

• The exercise of stock options indicates Maduck's confidence in the company's future performance.
• The purchase of shares under the purchase plan further demonstrates his investment in the company.

Negatives

• The sale of shares could be interpreted negatively, although it may be part of a pre-planned strategy under a 10b5-1 plan.
• The tax withholding indicates that Maduck is realizing gains from previously granted restricted stock units.

Risks

• Executive stock sales can sometimes be perceived negatively by the market, potentially leading to short-term price fluctuations.
• Changes in beneficial ownership could reflect shifts in executive compensation strategies or personal financial planning.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule of the new stock options suggests a continued commitment to the company over the next four years.

Industry Context

Executive stock transactions are common in the pharmaceutical industry and are closely monitored by investors for insights into management's confidence in the company's prospects. The use of 10b5-1 plans is a standard practice to avoid accusations of insider trading.

Comparison to Industry Standards

• Executive compensation packages in the pharmaceutical industry often include stock options and restricted stock units to align management's interests with those of shareholders.
• Companies like Gilead Sciences, Amgen, and Biogen also utilize similar equity-based compensation strategies.
• The vesting schedules and exercise prices of stock options are generally comparable across the industry, with variations based on company size and performance.

Stakeholder Impact

• Shareholders may monitor these transactions for insights into management's perspective on the company's value.
• Employees may be affected by changes in executive compensation structures.
• The transactions themselves are unlikely to have a direct impact on customers, suppliers, or creditors.

Key Dates